Alerta

PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF ADULT T-CELL LEUKEMIA

Resumen de: US2025236642A1

As a technique that can be used for cancer immunotherapy of adult T-cell leukemia (ATL), provided is a pharmaceutical composition for treatment or prevention of adult T-cell leukemia, the pharmaceutical composition containing a peptide consisting of an amino acid sequence of any one of SEQ ID NOs: 1 to 68.

COMPOSITIONS AND METHODS OF USE FOR THE INHIBITION OF TTK KINASE

Resumen de: WO2025155777A1

Disclosed herein are novel compounds that are Mpsl/TTK inhibitors. Also disclosed are compositions comprising the compounds and methods of using the compounds in treating various diseases. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.

TTK KINASE INHIBITORS AND METHODS OF USE

Resumen de: WO2025155780A1

Disclosed herein are novel compounds that are Mpsl/TTK inhibitors. Also disclosed herein are compositions comprising the compounds and methods of using the compounds in treating various diseases in a patient. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.

METHODS OF DETECTING LEUKEMIA STEM CELLS

Resumen de: WO2025155775A1

Methods of detecting leukemia stem cells are provided herein. Further provided are methods of diagnosing and treating AML as well as minimal residual disease or medium- or high-risk AML.

IMPROVED PRIME EDITING POLYPEPTIDE

Resumen de: WO2025153509A1

A first aspect of the invention relates to a variant prime editing polypeptide composed of a SpCas9 nickase fused to an engineered Moloney Murine leukaemia virus (M-MLV) reverse transcriptase, characterized by a mutation, relative to a reference sequence SEQ ID NO 001, selected from the group consisting of A277D; K1865T; and S237A. Another aspect of the invention relates to a combination of a first and second split PE variant polypeptide comprising split intein component at its C- and N-terminus, respectively, which, when both are present within a target cell, are capable of forming a fusion polypeptide comprising a functional prime editing polypeptide according to the first aspect of the invention. Other aspects of the invention relate to a combination medicaments and nucleic acid sequences facilitating the PE variant of the invention.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VEN/AZA RESISTANT ACUTE MYELOID LEUKEMIA

Resumen de: US2025235535A1

The disclosure describes T cells that express chimeric antigen receptors (CARs), as well as pharmaceutical compositions comprising T cells and methods of making and using such T cells. Particularly, this disclosure describes T cells expressing a CAR that binds to CD64, and methods of use in treating acute myeloid leukemia.

Crystalline forms of a Bruton's tyrosine kinase inhibitor

Nº publicación: AU2025205154A1 24/07/2025

Solicitante:

PHARMACYCLICS LLC
Pharmacyclics LLC

Resumen de: AU2025205154A1

CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo3,4-dpyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. CRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-(R)-3-(4-amino-3-(4- phenoxyphenyl)-1H-pyrazolo3,4-dpyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one,1 including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk in hibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. ul ' u l e s c r i b e d h e r e i n i s t h e r u t o n ' s t y r o s i n e k i n a s e ( t k ) i n h i b i t o r - ( ) - - ( - a m i n o - - ( - p h e n o x y p h e n y l ) - - p y r a z o l